These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36094202)

  • 21. Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor.
    Katsube T; Kezbor S; Shimizu R; Kubota R
    Infect Dis Ther; 2024 Mar; 13(3):597-607. PubMed ID: 38460082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
    Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
    J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
    Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
    J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects.
    Liu J; Zhao Q; Zhai Y; Wu X; Kai J; Ruan J; Wu M; Wu M; Zhou Z; Yan Y; Wu JJ; Qiu Y
    Expert Opin Investig Drugs; 2024 Aug; 33(8):867-876. PubMed ID: 38988285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
    Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
    Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants.
    Zhu T; Pawlak S; Toussi SS; Hackman F; Thompson K; Song W; Salageanu J; Winter E; Shi H; Winton J; Binks M
    Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1382-1393. PubMed ID: 36285536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Estimation of Residues Involving Resistance to the SARS-CoV-2 Main Protease Inhibitor Ensitrelvir Based on Virtual Alanine Scan of the Active Site.
    Mizuno A; Nakayoshi T; Kato K; Kurimoto E; Oda A
    Biol Pharm Bull; 2024; 47(5):967-977. PubMed ID: 38763751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
    Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
    J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
    Koshimichi H; Ishibashi T; Kawaguchi N; Sato C; Kawasaki A; Wajima T
    Clin Drug Investig; 2018 Dec; 38(12):1189-1196. PubMed ID: 30288682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.
    Pfeifer ND; Lo A; Bourdet DL; Colley K; Singh D
    Clin Transl Sci; 2021 Nov; 14(6):2556-2565. PubMed ID: 34318597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
    Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
    Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
    Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
    Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants.
    Cox DS; Rehman M; Khan T; Ginman K; Salageanu J; LaBadie RR; Wan K; Damle B
    Br J Clin Pharmacol; 2023 Nov; 89(11):3352-3363. PubMed ID: 37354048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.